OSLO, Norway--(BUSINESS WIRE)--Serodus AS (Serodus) today announced that it has entered into a license agreement with Roche (SIX:RO) (SIX:ROG) (OTCQX:RHHBY) for a selective serotonin-4 (5-HT4) antagonist for the potential treatment of heart failure (RO1160367).
